Skip to main content
SpringerLink
Log in

In Vitro Detection of Cellular Adjuvant Properties of Human Invariant Natural Killer T Cells

  • Protocol
  • First Online:
In Vitro Differentiation of T-Cells

Part of the book series: Methods in Molecular Biology ((MIMB,volume 2048))

Abstract

Invariant natural killer T (iNKT) cells are a subset of T lymphocytes that play a crucial role in the tumor surveillance. The activation of iNKT cells by their specific ligand α-galactosylceramide (α-GalCer) induces the activation of dendritic cells (DCs) via reciprocal interaction, which results in the generation of cellular immunity against cancer. Here we describe a method to detect DC-mediated cellular adjuvant properties of human iNKT cells in vitro.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Bendelac A, Savage PB, Teyton L (2007) The biology of NKT cells. Annu Rev Immunol 25:297–336. https://doi.org/10.1146/annurev.immunol.25.022106.141711

    Article  CAS  PubMed  Google Scholar 

  2. Molling JW, Moreno M, van der Vliet HJ, van den Eertwegh AJ, Scheper RJ, von Blomberg BM, Bontkes HJ (2008) Invariant natural killer T cells and immunotherapy of cancer. Clin Immunol 129:182–194. https://doi.org/10.1016/j.clim.2008.07.025

    Article  CAS  PubMed  Google Scholar 

  3. Fujii S, Shimizu K, Kronenberg M, Steinman RM (2002) Prolonged IFN-gamma-producing NKT response induced with alpha-galactosylceramide-loaded DCs. Nat Immunol 3(9):867–874. https://doi.org/10.1038/ni827

    Article  CAS  PubMed  Google Scholar 

  4. Kitamura H, Iwakabe K, Yahata T, Nishimura S, Ohta A, Ohmi Y, Sato M, Takeda K, Okumura K, Van Kaer L, Kawano T, Taniguchi M, Nishimura T (1999) The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells. J Exp Med 189(7):1121–1128

    Article  CAS  Google Scholar 

  5. Motohashi S, Nakayama T (2009) Invariant natural killer T cell-based immunotherapy for cancer. Immunotherapy 1(1):73–82. https://doi.org/10.2217/1750743x.1.1.73

    Article  CAS  PubMed  Google Scholar 

  6. Fujii SI, Shimizu K (2017) Exploiting antitumor immunotherapeutic novel strategies by deciphering the cross talk between invariant NKT cells and dendritic cells. Front Immunol 8:886. https://doi.org/10.3389/fimmu.2017.00886

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Liu H, Chen L, Liu J, Meng H, Zhang R, Ma L, Wu L, Yu S, Shi F, Li Y, Zhang L, Wang L, Feng S, Zhang Q, Peng Y, Wu Q, Liu C, Chang X, Yang L, Uemura Y, Yu X, Liu T (2017) Co-delivery of tumor-derived exosomes with alpha-galactosylceramide on dendritic cell-based immunotherapy for glioblastoma. Cancer Lett 411:182–190. https://doi.org/10.1016/j.canlet.2017.09.022

    Article  CAS  PubMed  Google Scholar 

  8. Nair S, Dhodapkar MV (2017) Natural killer T cells in Cancer immunotherapy. Front Immunol 8:1178. https://doi.org/10.3389/fimmu.2017.01178

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Krijgsman D, Hokland M, Kuppen PJK (2018) The role of natural killer T cells in cancer—a phenotypical and functional approach. Front Immunol 9:367. https://doi.org/10.3389/fimmu.2018.00367

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Gasser O, Sharples KJ, Barrow C, Williams GM, Bauer E, Wood CE, Mester B, Dzhelali M, Caygill G, Jones J, Hayman CM, Hinder VA, Macapagal J, McCusker M, Weinkove R, Painter GF, Brimble MA, Findlay MP, Dunbar PR, Hermans IF (2018) A phase I vaccination study with dendritic cells loaded with NY-ESO-1 and alpha-galactosylceramide: induction of polyfunctional T cells in high-risk melanoma patients. Cancer Immunol Immunother 67(2):285–298. https://doi.org/10.1007/s00262-017-2085-9

    Article  CAS  PubMed  Google Scholar 

  11. Lameris R, Schneiders FL, de Gruijl TD, van der Vliet HJ (2014) Exploiting the CD1d-iNKT cell axis for potentiation of DC-based cancer vaccines. Methods Mol Biol 1139:155–165. https://doi.org/10.1007/978-1-4939-0345-0_14

    Article  CAS  PubMed  Google Scholar 

  12. Gottschalk C, Mettke E, Kurts C (2015) The role of invariant natural killer T cells in dendritic cell licensing, cross-priming, and memory CD8(+) T cell generation. Front Immunol 6:379. https://doi.org/10.3389/fimmu.2015.00379

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Keller CW, Freigang S, Lunemann JD (2017) Reciprocal crosstalk between dendritic cells and natural killer T cells: mechanisms and therapeutic potential. Front Immunol 8:570. https://doi.org/10.3389/fimmu.2017.00570

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Liu TY, Uemura Y, Suzuki M, Narita Y, Hirata S, Ohyama H, Ishihara O, Matsushita S (2008) Distinct subsets of human invariant NKT cells differentially regulate T helper responses via dendritic cells. Eur J Immunol 38(4):1012–1023. https://doi.org/10.1002/eji.200737838

    Article  CAS  PubMed  Google Scholar 

  15. Uemura Y, Liu TY, Narita Y, Suzuki M, Nakatsuka R, Araki T, Matsumoto M, Iwai LK, Hirosawa N, Matsuoka Y, Murakami M, Kimura T, Hase M, Kohno H, Sasaki Y, Ichihara Y, Ishihara O, Kikuchi H, Sakamoto Y, Jiao SC, Senju S, Sonoda Y (2009) Cytokine-dependent modification of IL-12p70 and IL-23 balance in dendritic cells by ligand activation of Valpha24 invariant NKT cells. J Immunol 183(1):201–208. https://doi.org/10.4049/jimmunol.0900873

    Article  CAS  PubMed  Google Scholar 

  16. Nishimura T, Kaneko S, Kawana-Tachikawa A, Tajima Y, Goto H, Zhu D, Nakayama-Hosoya K, Iriguchi S, Uemura Y, Shimizu T, Takayama N, Yamada D, Nishimura K, Ohtaka M, Watanabe N, Takahashi S, Iwamoto A, Koseki H, Nakanishi M, Eto K, Nakauchi H (2013) Generation of rejuvenated antigen-specific T cells by reprogramming to pluripotency and redifferentiation. Cell Stem Cell 12(1):114–126. https://doi.org/10.1016/j.stem.2012.11.002

    Article  CAS  PubMed  Google Scholar 

  17. Kitayama S, Zhang R, Liu TY, Ueda N, Iriguchi S, Yasui Y, Kawai Y, Tatsumi M, Hirai N, Mizoro Y, Iwama T, Watanabe A, Nakanishi M, Kuzushima K, Uemura Y, Kaneko S (2016) Cellular adjuvant properties, direct cytotoxicity of re-differentiated Valpha24 invariant NKT-like cells from human induced pluripotent stem cells. Stem cell reports 6(2):213–227. https://doi.org/10.1016/j.stemcr.2016.01.005

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Yamada D, Iyoda T, Vizcardo R, Shimizu K, Sato Y, Endo TA, Kitahara G, Okoshi M, Kobayashi M, Sakurai M, Ohara O, Taniguchi M, Koseki H, Fujii SI (2016) Efficient regeneration of human Valpha24(+) invariant natural killer T cells and their anti-tumor activity in vivo. Stem Cells 34(12):2852–2860. https://doi.org/10.1002/stem.2465

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This study was supported by grants from the Grants-in-Aid 17K10717 and 17K10806 from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan; the National Cancer Center Research and Development Fund (28-A-8); and the Practical Research for Innovative Cancer Control from Japan Agency for Medical Research and Development (AMED 15ck0196002h0103). We thank Mrs. M. Ozaki and K. Kobayashi (National Cancer Center) for secretarial support.

Author information

Author notes

  1. Rong Zhang and Shuichi Kitayama are co-first authors, and Shin Kaneko and Yasushi Uemura are co-senior authors.

Authors and Affiliations

  1. Division of Cancer Immunotherapy, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Japan

    Rong Zhang, Norihiro Ueda, Yumi Tokumitsu & Yasushi Uemura

  2. Division of Immunology, Aichi Cancer Center Research Institute, Nagoya, Japan

    Rong Zhang, Norihiro Ueda & Yasushi Uemura

  3. Shin Kaneko Laboratory, Department of Cell Growth and Differentiation, Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan

    Shuichi Kitayama, Norihiro Ueda & Shin Kaneko

  4. Key Laboratory of Cancer Center, Chinese PLA General Hospital, Beijing, China

    Tianyi Liu

  5. Department of Gastroenterological and Transplant Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan

    Hiroaki Mashima & Hideki Ohdan

Authors
  1. Rong Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shuichi Kitayama
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tianyi Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Norihiro Ueda
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yumi Tokumitsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hiroaki Mashima
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hideki Ohdan
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Shin Kaneko
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yasushi Uemura
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Shin Kaneko Laboratory, Department of Cell Growth and Differentiation, Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan

    Shin Kaneko

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Science+Business Media, LLC, part of Springer Nature

About this protocol

Check for updates. Verify currency and authenticity via CrossMark

Cite this protocol

Zhang, R. et al. (2019). In Vitro Detection of Cellular Adjuvant Properties of Human Invariant Natural Killer T Cells. In: Kaneko, S. (eds) In Vitro Differentiation of T-Cells. Methods in Molecular Biology, vol 2048. Humana, New York, NY. https://doi.org/10.1007/978-1-4939-9728-2_13

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-9728-2_13

  • Published:

  • Publisher Name: Humana, New York, NY

  • Print ISBN: 978-1-4939-9727-5

  • Online ISBN: 978-1-4939-9728-2

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation